KX01 is an inhaled anti-inflammatory treatment for patients developing Bronchiolitis Obliterans Syndrome (BOS) after lung transplant and allogenic stem cell transplant. Currently, no treatments are approved by FDA.
KX01 will address inflammation, fibrosis, and other key factors that contribute to the progression of the disease with the aim of improving outcomes for patients with BOS.
BOS is a significant long-term complication in lung transplant recipients. BOS occurs in 50 % of all lung transplant patient within 5 years post lung transplant.
BOS is a progressive and potentially life-threatening condition affecting the small airways of the lungs. Patients with BOS has a poor prognosis with median survival of 2-3 years post-diagnosis.